FDA Spending Feels Sequester’s Pinch As Program Managers Finalize FY ’13 Plans
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency leadership’s commitment to saving current jobs has kept morale high, COO Walter Harris says, but more challenges lie ahead as managers try to balance honoring industry performance commitments with other goals.
You may also be interested in...
Rx Misbranding Penalties Should Be Stronger To Stop Counterfeiting, FDA Says
Industry also seems supportive of the idea, while Pew touts the power of the power of track-and-trace as a deterrent.
Track-And-Trace: With Deadline a Year Away, Some Lessons from Early Adopters
EMD Serono has been tracking Serostim packages since 2002; J&J is using Prezista 600 mg as a trial run for serialization.
Drug Safety In Pregnant Women: FDA Seeks Alternatives To Registries
Stakeholder meeting will address poor enrollment rates and other issues that undermine the utility of pregnancy registries, as well as the use of alternatives, such as case control studies and claims-based database studies.